Synopsis:

Indian CDMO shares surged on October 10 after the U.S. Senate passed the Biosecure Act, boosting prospects for Indian biotech exporters as the Act limits federal procurement from Chinese companies.

Shares of Indian Contract Development and Manufacturing Organization (CDMO) players rallied on October 10 following the U.S. Senate’s passage of the Biosecure Act. The legislation, embedded within the National Defense Authorization Act (NDAA), passed with 77 votes in favor and 20 against.

The Act restricts federal agencies from procuring, contracting with, or using biotech equipment or services from companies of concern originating from China, creating potential opportunities for alternative global suppliers.

According to sources, India, which has the highest number of USFDA-approv

See Full Page